Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + ongericimab
- Development stage
- Phase 1
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Toripalimab + ongericimab is a combination therapy consisting of two monoclonal antibodies developed by Junshi Biosciences. Toripalimab (JS001, TUOYI) is a recombinant humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands, enhancing T-cell immune responses against cancer cells. Ongericimab (JS002) is a recombinant humanized anti-PCSK9 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol metabolism. This combination is being investigated in clinical trials for patients with advanced cancer who have failed standard therapy or have no standard therapy options available.
- Brand names
- TUOYI + ongericimab
- Other names
- toripalimab + JS002JS001 + ongericimabTUOYI + JS002
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on toripalimab + ongericimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + ongericimab.